Lori Ellis

Lori was formerly head of insights at BioSpace. She has been part of an award-winning marketing team and has won a Muse Creative award, a Vega award and several Adobe awards in collaborative team projects for her audio narration work. While she has covered all elements of the drug development process, her primary focuses are women’s health issues, the economic climate, and the ever-evolving impact of technology – specifically artificial intelligence – on the pharmaceutical industry.

This week on The Weekly we talk struggles with ⁠GLP-1 drug shortages⁠ and what that might mean for Novo and Lilly competitors; Regeneron and Sanofi positive results for ⁠⁠⁠Dupixent⁠⁠⁠ in COPD. Plus, Merck ⁠buys Caraway⁠, Beigene’s ⁠deal⁠ with Ensem, ⁠ups⁠ and ⁠downs⁠ for Flagship.
CRISPR gene-editing has had its first ever approval in the UK. Will the FDA follow suit? What can patients expect the price tag to be?
Both the White House and Congress have proposed legislation for the appropriate use of AI while the FDA continues to serve as the gatekeeper for patient privacy and safety.
This is part one of a discussion focused upon data bias, accuracy, access and the future of AI in drug development. Topics explored are ROI, human bias, data challenges, data management plans, and human expertise.
FDA
A Discussion with IQVIA’s Michelle Gyzen Sr. Director, Regulatory Affairs and Drug Development Solutions
With 88% of life sciences organizations using or planning to use AI in recruitment and/or hiring, AI regulation is a priority for the industry.
The first annual BioTechX USA, held in Santa Clara in September, bridged the communication gap by bringing together life sciences leaders in all areas of the industry.